Updating and Refining of Economic Evaluation of Rotavirus Vaccination in Spain: A Cost-Utility and Budget Impact Analysis
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Targeted rotavirus vaccination with Rotarix® is cost-effective in Spain. Universal vaccination strategies are not efficient unless vaccine prices decrease significantly. Further price reductions are needed for widespread rotavirus vaccine adoption.
Area Of Science
- Public Health
- Health Economics
- Vaccinology
Background
- Rotavirus diseases pose a significant health burden, yet universal vaccination is not implemented in Spain.
- Current vaccination strategies in Spain are targeted, primarily focusing on preterm infants.
Purpose Of The Study
- To evaluate the cost-utility of extending Spain's rotavirus vaccination strategy from targeted to universal coverage.
- To compare targeted, universal, and no vaccination strategies using Rotarix® and RotaTeq® from societal and Spanish National Health System perspectives.
Main Methods
- A de novo cohort-based Markov model was developed to simulate rotavirus infection and vaccination outcomes.
- Systematic reviews were conducted to gather data on efficacy, effectiveness, safety, costs, and utilities.
- Cost-utility analysis was performed, calculating the Incremental Cost-Utility Ratio (ICUR) in EUR/QALY (Quality-Adjusted Life Year).
Main Results
- Targeted vaccination with Rotarix® yielded an ICUR of EUR 23,638/QALY compared to no vaccination.
- All other evaluated vaccination strategies, including universal vaccination, had ICURs exceeding EUR 30,000/QALY.
- Sensitivity analysis identified vaccine price as the key factor influencing the efficiency of universal vaccination.
Conclusions
- From a societal perspective, considering a threshold of EUR 25,000/QALY, only targeted vaccination with Rotarix® is deemed efficient.
- Universal vaccination strategies would become efficient with substantial price reductions: 36.9% for Rotarix® and 44.6% for RotaTeq®.
- Current vaccination policies in Spain favor targeted approaches due to cost-effectiveness.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.